1456907-39-3
1456907-39-3
Chemical Structure
NCD38
- CAS No.: 1456907-39-3
- Formula:C35H36ClN3O2
- Molecular Weight:566.13
InChIKey: KYDFMNLSOYZOTR-OMYKBPHGSA-N
SMILES: O=C(C1=CC=C(C2=CC=CC=C2)C=C1)N[C@H](C(NCC3=CC(Cl)=CC=C3)=O)CCCCNC4C(C5=CC=CC=C5)C4
Biological Activity: NCD38 is a Lysine-specific demethylase 1 (LSD1) inhibitor with a target IC50 of 0.59 μM. NCD38 selectively disrupts LSD1-GFI1B interactions, dissociates LSD1 and CoREST from the ERG super-enhancer. NCD38 increases apoptosis-related protein levels, induces apoptosis and reduces SOX2 and Oct4 levels. NCD38 can be used for the research of acute myeloid leukemia[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NCD38 | NCD38 is a Lysine-specific demethylase 1 (LSD1) inhibitor with a target IC50 of 0.59 μM. NCD38 selectively disrupts LSD1-GFI1B interactions, dissociates LSD1 and CoREST from the ERG super-enhancer. NCD38 increases apoptosis-related protein levels, induces apoptosis and reduces SOX2 and Oct4 levels. NCD38 can be used for the research of acute myeloid leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yamamoto R, et al. Selective dissociation between LSD1 and GFI1B by a LSD1 inhibitor NCD38 induces the activation of ERG super-enhancer in erythroleukemia cells. Oncotarget. 2018;9(30):21007-21021. Published 2018 Apr 20. [Content Brief]
- [2]. Sugino N, et al. A novel LSD1 inhibitor NCD38 ameliorates MDS-related leukemia with complex karyotype by attenuating leukemia programs via activating super-enhancers. Leukemia. 2017 Nov;31(11):2303-2314. [Content Brief]
- [3]. Dai XJ, et al. Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective. J Med Chem. 2020;63(23):14197-14215. [Content Brief]
